Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non Operating Income: 2011-2025

Historic Other Non Operating Income for Northwest Biotherapeutics (NWBO) over the last 13 years, with Sep 2025 value amounting to -$12.5 million.

  • Northwest Biotherapeutics' Other Non Operating Income fell 83.42% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.7 million, marking a year-over-year decrease of 444.75%. This contributed to the annual value of -$17.3 million for FY2024, which is 143.55% down from last year.
  • Northwest Biotherapeutics' Other Non Operating Income amounted to -$12.5 million in Q3 2025, which was down 176.99% from -$4.5 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Other Non Operating Income's 5-year high stood at $145.8 million during Q4 2021, with a 5-year trough of -$17.2 million in Q3 2022.
  • Its 3-year average for Other Non Operating Income is -$4.0 million, with a median of -$4.5 million in 2025.
  • Over the last 5 years, Northwest Biotherapeutics' Other Non Operating Income had its largest YoY gain of 376.58% in 2024, and its largest YoY loss of 732.19% in 2024.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Other Non Operating Income stood at $145.8 million in 2021, then slumped by 106.94% to -$10.1 million in 2022, then skyrocketed by 111.51% to $1.2 million in 2023, then crashed by 732.19% to -$7.4 million in 2024, then tumbled by 83.42% to -$12.5 million in 2025.
  • Its Other Non Operating Income was -$12.5 million in Q3 2025, compared to -$4.5 million in Q2 2025 and -$7.3 million in Q1 2025.